GlassScriptPhysician profile
Wallace P Chan
NPI 1164624334
$2,406.84
in general payments reported to CMS, 2019-2025
49 companies · $591 in 2025
The $591 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $116 · 2021: $334 · 2023: $304 · 2024: $553 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $276.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $211.83 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Daiichi Sankyo INC. | $180.57 | 2019-2025 | Vanflyta |
| Dova Pharmaceuticals | $125.00 | 2021 | |
| Pfizer INC. | $104.92 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $88.78 | 2023-2025 | Tazverik, Onivyde |
| Springworks Therapeutics, INC. | $81.69 | 2024-2025 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $75.88 | 2021-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $71.14 | 2019-2023 | Epkinly, Imbruvica |
| Agios Pharmaceuticals, INC. | $67.89 | 2025 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $65.10 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $60.55 | 2024 | Provenge |
| Menarini Silicon Biosystems, INC. | $56.86 | 2023-2024 | Cellsearch |
| Janssen Biotech, INC. | $52.78 | 2019-2020 | |
| Celgene Corporation | $52.57 | 2019-2024 | Reblozyl |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.